Recent Updates
Recently added Catalysts

Ascentage Pharma Group International - American Depository Shares

AAPGFDA catalysts, PDUFA dates & pipeline intelligence
$12.44
▼ -0.57 · -4.4%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full AAPG financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $12.4452W HIGH $33.09
Volume
1.49 K
Value Traded
18.78 K
Short % Float
-
Days to Cover
1.0
-17.18%Week
-21.86%1 Month
-28.18%3 Month
-39.79%6 Month
+21.8%5 Year
+21.8%All Time

Cash Data

Unlock AAPG cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
1.16 B
EPS (TTM)
-1.94
P/E Ratio
-
Ent. Value
1.90 B
Total Shares
93.39 M
Float Shares
-
Insiders
-
Institutions
0.02%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Phase 1b data presentation
Olverembatinib + lisaftoclax
pediatric relapsed/refractory Philadelphia chromosome · positive acute lymphoblastic leukemia (R/R Ph+ ALL)
Phase 1bSmall MoleculesOncology
Unlock every AAPG catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

AAPG Catalyst Timeline

Dated clinical, regulatory and corporate events for Ascentage Pharma Group International - American Depository Shares

Catalyst Timeline

Dated clinical, regulatory & corporate events for Ascentage Pharma Group International - American Depository Shares

146Total events
17Upcoming
22Tier-1 (high impact)
2024 to 2027Coverage

Upcoming catalysts 2

T3Poster Presentation
Subscribe to view catalyst details
LisaftoclaxApproved
T3Poster Presentation
Subscribe to view catalyst details
APG-5918

Event history 50

▲Breakthrough Therapy DesignationLisaftoclaxApprovedDesignation
NMPA CDE grants Breakthrough Therapy Designation to lisaftoclax plus acalabrutinib in treatment-naïve CLL/SLL
treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)source ↗
▲Poster PresentationLisaftoclaxApprovedPresentation
Updated results of POLARIS-1 Part 1: olverembatinib combined with low-intensity chemotherapy in newly diagnosed Ph+ ALL
Philadelphia chromosome-positive acute lymphoblastic leukemiasource ↗
▲Poster PresentationLisaftoclaxApprovedPresentation
Correlation of baseline characteristics with prognosis in CLL/SLL patients treated with lisaftoclax in pivotal Phase 2 study
chronic lymphocytic leukemia/small lymphocytic lymphomasource ↗
◆Poster PresentationLisaftoclaxApprovedPresentation
Efficacy of Olverembatinib in CP-CML with prior resistance to ponatinib or asciminib and ASXL1 mutations
Chronic-phase chronic myeloid leukemia (CP-CML) with prior resistance to ponatinib or asciminib and ASXL1 mutationssource ↗
◆Poster PresentationLisaftoclaxApprovedPresentation
Correlation of baseline characteristics with prognosis in CLL/SLL patients treated with Lisaftoclax in a pivotal Phase 2 study
Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)source ↗
◆Poster PresentationLisaftoclaxApprovedPresentation
Safety and preliminary efficacy of Olverembatinib combined with Lisaftoclax in pediatric R/R Ph+ ALL: results of a Phase 1b study
Relapsed/refractory Ph+ ALL (pediatric)source ↗
◆Poster PresentationLisaftoclaxApprovedPresentation
Updated clinical and translational results of Olverembatinib in SDH-deficient tumors
succinate dehydrogenase (SDH)-deficient tumorssource ↗
◆Poster PresentationLisaftoclaxApprovedPresentation
Global multicenter, open-label, randomized, phase 3 registrational study of Lisaftoclax in CLL/SLL: GLORA trial in progress
previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)source ↗
▲Oral PresentationLisaftoclaxApprovedPresentation
Rapid oral presentation of Phase Ib data for olverembatinib + blinatumomab in CML-LBP and Ph+ BCP-ALL at ASCO 2026
lymphoid blast phase chronic myeloid leukemia (CML-LBP) or Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemia (Ph+ BCP-ALL)source ↗
▲Oral PresentationAPG-115Presentation
First dataset of alrizomadlin (APG-115) as monotherapy or in combination with lisaftoclax in pediatric solid tumors presented at ASCO 2026
pediatric solid tumors (rhabdomyosarcoma, Ewing sarcoma, neuroblastoma, other soft-tissue sarcomas)source ↗
Unlock the full AAPG catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How AAPG actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
2026-06-13Lisaftoclax (APG-2575) Phase 2 data readout Phase 2
Unlock 7 more AAPG historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

Pipeline Score
Pipeline Value
Valuation Signal
8
Drugs Scored
rNPV / MCap
Top Drug
Top 10%
Micro Cap
(rank 73 of 723)
Percentile Rank
Showing 25 of 26 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
Lisaftoclax Small MoleculesNCT04215809CLL/SLLPhase 3 RECRUITING 888Jun 30, 2027
Lisaftoclax Small MoleculesNCT06641414Higher-risk Myelodysplastic SyndromePhase 3 RECRUITING 490Dec 1, 2029
APG-2575 Small MoleculesNCT06389292Acute Myeloid LeukemiaPhase 3 RECRUITING 486Mar 26, 2029
APG-2575 Small MoleculesNCT06182969SLEPhase 1/2 RECRUITING 40Dec 1, 2026
Lisaftoclax Small MoleculesNCT04501120Relapsed/Refractory Acute Myeloid LeukaemiaPhase 1/2 RECRUITING 682Sep 1, 2029
APG-2575 Small MoleculesNCT03913949Chronic Lymphocytic LeukemiaPhase 2 ACTIVE NOT_RECRUITING 272Dec 31, 2026
Olverembatinib Small MoleculesNCT04260022Chronic Myeloid LeukemiaPhase 3 RECRUITING 575Mar 31, 2030
Olverembatinib Small MoleculesNCT06051409Ph+ ALLPhase 3 RECRUITING 350Jun 30, 2029
Olverembatinib Small MoleculesNCT06640361GISTPhase 3 RECRUITING 40Jun 30, 2029
HQP1351 Small MoleculesNCT03594422Gastrointestinal Stromal Tumor (GIST)Phase 1 RECRUITING 100Dec 1, 2028
APG-115 Small MoleculesNCT04785196LiposarcomaPhase 1/2 RECRUITING 95Jan 1, 2027
APG-115 Small MoleculesNCT03611868Unresectable or Metastatic Melanoma or Advanced Solid TumorsPhase 1/2 ACTIVE NOT_RECRUITING 230Dec 30, 2025
APG-115 Small MoleculesNCT05701306NeuroblastomaPhase 1/2 RECRUITING 100Dec 31, 2027
APG-115 Small MoleculesNCT04496349T-Prolymphocytic LeukemiaPhase 2 RECRUITING 78May 31, 2027
APG-5918 Small MoleculesNCT05773586AnemiaPhase 1 RECRUITING 105Jul 15, 2028
APG-2449 Small MoleculesNCT03917043Advanced Solid CancerPhase 1 RECRUITING 165Jan 1, 2028
APG-2449 Small MoleculesNCT06687070Platinum-resistant Recurrent Ovarian CancerPhase 1 RECRUITING 90May 1, 2028
APG-3288 Small MoleculesNCT07424833Relapsed/Refractory Hematological MalignanciesPhase 1 RECRUITING 180Dec 1, 2031
APG-2575 Small MoleculesCompletedNCT04260217Waldenstrom MacroglobulinemiaPhase 1 COMPLETED 46Aug 13, 2025
HQP1351 Small MoleculesCompletedNCT03882281Chronic Myeloid Leukemia, Chronic PhasePhase 2 COMPLETED 156Nov 16, 2019
HQP1351 Small MoleculesCompletedNCT04126707Chronic Myeloid Leukemia (CML)Phase 1 COMPLETED 6Jan 13, 2020
APG-115 Small MoleculesCompletedNCT02935907Patients With Advanced Solid Tumor or LymphomaPhase 1 COMPLETED 50Jun 28, 2019
APG-1252 Small MoleculesCompletedNCT04001777EGFR Positive Non-small Cell Lung CancerPhase 1 COMPLETED 73May 27, 2025
APG-1252 Small MoleculesCompletedNCT03080311Small Cell Lung CancerPhase 1 COMPLETED 50Jul 17, 2020
APG-1387 Small MoleculesCompletedNCT03386526Advanced Solid Tumors or Hematologic MalignanciesPhase 1 COMPLETED 90Nov 30, 2022
Unlock the AAPG pipeline intelligence model
PTRS, rNPV, enrollment velocity, trial design quality and ML risk signals for every asset above.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every AAPG program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
olverembatinib chronic myeloid leukemiaPhase 32026-06-14deep and durable responses in patients with chronic-phase CML (CML-CP) without the T315I mutationRead MoreAscentage Pharma Presents Multiple Clinical Updates at EHA2026 CongressRead More
Scroll for more · summaries link to the source press release
Unlock every AAPG trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock AAPG insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
Zhai YifanOfficer (Chief Medical Officer)Option 95,575 1,193,569 held$0.00 05/21/2026
Unlock the full AAPG insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Fund % of Portfolio Current MV Shares Owned Activity
No hedge fund reported a 13F position in AAPG for Q3 2026.
Unlock every fund holding AAPG
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in AAPG
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see AAPG ownership
Insider and institutional ownership, quarter by quarter.

AAPG Short Interest

Shares sold short, counted twice a month.

-
Short % of Float
of tradable shares sold short
9.1K
Shares Sold Short
-49.8% vs prior count
1.0 Low
Days to Cover
trading days of normal volume to buy every short share back
8.9K
Avg Daily Volume
the average used for days to cover
Unlock AAPG short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Option Volume

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
Unlock AAPG option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live AAPG option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock AAPG options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How AAPG ranks across every disease it competes in

Competitive Position is a premium feature
See how AAPG ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

AAPG News

AAPG
Nov 15, 2026
AAPGFDA Updates
▼ -9.1%on this news

Ascentage Pharma Announces Inclusion of Lisaftoclax in China's 2026 National Reimbursement Drug List and Successful Renewal of Coverage for Olverembatinib

Ascentage Pharma announced that its drugs, lisaftoclax and olverembatinib, are included in China's 2026 National Reimbursement Drug List. Lisaftoclax is now available for CLL/SLL patients, while olverembatinib's coverage has been renewed for CML patients. This development enhances patient access to these innovative therapies, effective from January 1, 2027.

Read more →
AAPG
Nov 4, 2026
AAPGConferences/Events

Ascentage Pharma to Present Data from Multiple Trials, Including an Oral Presentation of APG-5918 at ASH 2026

Ascentage Pharma announced that multiple studies, including APG-5918, will be presented at the ASH 2026 Annual Meeting. APG-5918, an EED inhibitor, shows promising efficacy in treating relapsed/refractory T-cell lymphoma. Additionally, data on combination therapies of olverembatinib and lisaftoclax demonstrate high response rates in various hematologic malignancies.

Read more →
AAPG
Nov 3, 2026
AAPGConferences/Events

Ascentage Pharma to Participate in Two Upcoming Investor Conferences in London

Ascentage Pharma announced its participation in two investor conferences in London on November 16 and 17, 2026. The events will include company presentations and one-on-one meetings with investors. Ascentage is recognized for its innovative therapies, including Olverembatinib and Lisaftoclax, which target unmet medical needs in cancer.

Read more →
AAPG
Oct 20, 2026
AAPGFDA Updates

Ascentage Pharma’s Lisaftoclax Granted Breakthrough Therapy Designation in China for Treatment-Naïve CLL/SLL

Ascentage Pharma's lisaftoclax has been granted Breakthrough Therapy Designation in China for treatment-naïve CLL/SLL patients. This designation allows for expedited development and review, addressing significant clinical needs. The drug, in combination with acalabrutinib, aims to improve treatment outcomes for patients with limited options after standard therapies.

Read more →
AAPG
Sep 2, 2026
AAPGConferences/Events

Ascentage Pharma to Participate in Four Upcoming Investor Conferences

Ascentage Pharma Group International will participate in four upcoming investor conferences in New York, showcasing its innovative therapies and recent product approvals. The conferences include presentations and one-on-one meetings, allowing investors to engage with the company's management. Ascentage continues to develop therapies targeting unmet medical needs in cancer, bolstered by a strong pipeline and strategic partnerships.

Read more →
AAPG
Aug 19, 2026
AAPGGeneral

Ascentage Pharma Reports 2026 Interim Unaudited Financial Results and Provides Business Updates

Ascentage Pharma reported first-half 2026 revenue of US$44.5 million, a 29 percent increase from the prior year period. The company also announced the appointments of Dr. Faical Miyara and Mr. James Ziegler to its executive leadership team. Nine registrational Phase III clinical trials are currently in progress worldwide. These updates accompany the release of the company's interim unaudited financial results.

Read more →
AAPG
Aug 13, 2026
AAPGConferences/Events

Ascentage Pharma to Participate in the Evercore 2nd Annual China Biotech Summit

Ascentage Pharma will participate in the Evercore 2nd Annual China Biotech Summit from August 17-19, 2026. The company's management will engage in a fireside chat and one-on-one investor meetings during the event. Ascentage Pharma is recognized for its innovative therapies targeting cancer, including its approved products and ongoing clinical trials.

Read more →
AAPG
Aug 5, 2026
AAPGConferences/Events

Ascentage Pharma to Report 2026 Six Month Interim Results and Provide Corporate Update on August 19, 2026

Ascentage Pharma Group International will announce its six-month interim results for 2026 on August 19, 2026. The company will host investor webcasts in both Mandarin and English to discuss these results and provide business updates. Ascentage Pharma is recognized for its innovative cancer therapies and has multiple ongoing Phase III trials.

Read more →
AAPG
Aug 2, 2026
AAPGGeneral

Ascentage Pharma Appoints Dr. Faiçal Miyara as Chief Business Officer and Jim Ziegler as Chief Commercial Officer

Ascentage Pharma has appointed Dr. Faiçal Miyara as Chief Business Officer and Jim Ziegler as Chief Commercial Officer. These appointments aim to enhance the company's global business development and commercialization efforts, particularly in the oncology sector. Both executives bring extensive experience in their respective fields, which aligns with Ascentage's strategy to expand its global footprint and advance its innovative therapies.

Read more →
AAPG
Jul 26, 2026
AAPGGeneral

Ascentage Pharma Chairman and CEO Dr. Dajun Yang Named to The Medicine Maker Power List 2026

Ascentage Pharma's Chairman and CEO, Dr. Dajun Yang, has been named No. 3 in The Medicine Maker Power List 2026 for his contributions to oncology and drug development. The recognition highlights his leadership in advancing innovative cancer therapies, including olverembatinib and lisaftoclax. Ascentage Pharma continues to progress with multiple global Phase III trials, addressing significant unmet medical needs in cancer treatment.

Read more →
AAPG
Jun 14, 2026
AAPGPhases

Ascentage Pharma Presents Multiple Clinical Updates at EHA2026 Congress

Ascentage Pharma presented 17 clinical updates at the EHA2026 Congress, showcasing the efficacy of olverembatinib and lisaftoclax in treating hematologic malignancies. Olverembatinib demonstrated significant responses in chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. Lisaftoclax showed promising results in pediatric patients with relapsed/refractory conditions. These findings support the ongoing development of these therapies.

Read more →
AAPG
Jun 12, 2026
AAPGGeneral

VOLUNTARY ANNOUNCEMENT PURCHASE OF SHARES BY THE TRUSTEE FOR THE PURPOSE OF THE 2022 RSU SCHEME

Ascentage Pharma Group International announced a voluntary share purchase by the Trustee for the 2022 RSU Scheme. On June 11, 2026, the Trustee acquired 110,000 existing shares for a total consideration of HK$3,671,094, representing approximately 0.0294% of the total issued shares. This purchase aims to fulfill the company's obligations related to the RSUs upon their vesting. No new grants have been made under the RSU Scheme aside from initial awards since June 2022, indicating a steady approach to equity compensation.

Read more →
AAPG
May 31, 2026
AAPGPhases

Ascentage Pharma Presents Updated Clinical Data for Olverembatinib as Second-Line Therapy in CML-CP at ASCO 2026

Ascentage Pharma presented updated clinical data for olverembatinib as a second-line therapy for chronic-phase chronic myeloid leukemia (CML-CP) at the 2026 ASCO Annual Meeting. The study reported a complete cytogenetic response rate of 91.3% and a major molecular response rate of 60.9% after 24 cycles of treatment. The drug demonstrated a manageable safety profile, with no new safety signals identified, reinforcing its potential in treating patients who failed first-line therapy.

Read more →
AAPG
May 31, 2026
AAPGConferences/Events

Ascentage Pharma Presents Its First Dataset on MDM2-p53 Inhibitor Alrizomadlin (APG-115) in Pediatric Solid Tumors at ASCO 2026

Ascentage Pharma presented its first dataset on alrizomadlin (APG-115), an MDM2-p53 inhibitor, at the 2026 ASCO Annual Meeting. The data showed promising antitumor activity in pediatric patients with relapsed/metastatic rhabdomyosarcoma and other soft-tissue sarcomas. Alrizomadlin demonstrated a favorable safety profile and was included in China's SPARK Plan for further development in pediatric oncology.

Read more →
AAPG
May 31, 2026
AAPGPhases

Ascentage Pharma Presents Data on Olverembatinib in CML-LBP and Ph+ BCP-ALL at ASCO 2026

Ascentage Pharma presented promising data on olverembatinib combined with blinatumomab at the 2026 ASCO Annual Meeting. The Phase Ib study showed high response rates in patients with relapsed/refractory Ph+ BCP-ALL and CML-LBP. The combination therapy was well tolerated, indicating its potential as a novel treatment strategy for these challenging hematologic malignancies.

Read more →
AAPG
May 28, 2026
AAPGGeneral

ASCENTAGE PHARMA GROUP INTERNATIONAL

Ascentage Pharma Group International made a voluntary announcement regarding the 2022 RSU Scheme. This announcement details the purchase of 50,000 existing shares by the Trustee on-market for the purpose of satisfying RSUs at vesting. As of May 28, 2026, the total number of purchased shares under the scheme amounts to 2,315,000 shares. The Trustee will hold these shares in accordance with the rules of the RSU Scheme and will not exercise voting rights attached to them.

Read more →
AAPG
May 22, 2026
AAPGConferences/Events

Ascentage Pharma Releases Latest Clinical Data from Multiple Trials at ASCO 2026

Ascentage Pharma announced the presentation of six abstracts at the 2026 ASCO Annual Meeting, showcasing data from ongoing studies of its lead drug candidates. Notably, olverembatinib demonstrated high response rates in patients with chronic myeloid leukemia and other hematological malignancies. The meeting will occur from May 29 to June 2, 2026, in Chicago, IL.

Read more →
AAPG
May 22, 2026
AAPGGeneral

POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON MAY 20, 2026

Ascentage Pharma Group International held its annual general meeting on May 20, 2026, where all proposed resolutions were approved. A total of 373,348,863 shares were entitled to vote, with significant support for financial statements and director re-elections. Notably, resolutions related to granting RSUs and Options to key executives were also approved, although the executives abstained from voting. The company aims to continue its operational growth and leadership structure as indicated by the positive AGM results.

Read more →
AAPG
May 13, 2026
AAPGConferences/Events

Ascentage Pharma to Present 17 Clinical Advances at 2026 European Hematology Association Congress

Ascentage Pharma announced that it will present 17 clinical advances at the upcoming EHA2026 Congress in Stockholm, Sweden. The presentations will include key data on Olverembatinib and Lisaftoclax, two innovative therapies for hematologic malignancies. This event is a major platform for sharing research advancements in hematology.

Read more →

About Ascentage Pharma Group International - American Depository Shares

828 employees ascentage.cn
BIOPHARMAWATCH ELITE
Trade the next AAPG catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime